Repligen (NASDAQ:RGEN) Upgraded to Hold at StockNews.com

Repligen (NASDAQ:RGEN) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Several other equities analysts also recently issued reports on RGEN. Stephens reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company began coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Finally, Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Up 0.6 %

RGEN stock opened at $142.58 on Friday. The firm has a market cap of $7.99 billion, a PE ratio of -385.34, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 10.44. The firm’s fifty day moving average is $140.26 and its 200 day moving average is $143.44. Repligen has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm posted $0.23 earnings per share. On average, research analysts forecast that Repligen will post 1.52 EPS for the current year.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently bought and sold shares of RGEN. Andra AP fonden purchased a new position in Repligen during the second quarter worth about $25,000. International Assets Investment Management LLC purchased a new position in Repligen during the second quarter worth about $33,000. UMB Bank n.a. raised its stake in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Lazard Asset Management LLC raised its stake in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the period. Finally, Blue Trust Inc. raised its stake in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.